Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Short Term Solifenacin for Overactive Bladder on the Female Urinary Microbiome

Next Previous
Trial Profile

The Effect of Short Term Solifenacin for Overactive Bladder on the Female Urinary Microbiome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Pharmacodynamics

Most Recent Events

  • 30 Oct 2015 Trial design has been changed from cohort, observational to interventional, open, parallel as reported by ClinicalTrials.gov record.
  • 30 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 08 Sep 2014 Planned End Date changed from 1 Jul 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top